研究单位:[1]Hebei Medical University Fourth Hospital河北医科大学第四医院
研究目的:
To evaluate the efficacy and safety of P nab-paclitaxel combined with carboplatin versus paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamide in the neoadjuvant treatment of triple negative breast cancer.